dr. makker on safety signals with lenvatinib and pembrolizumab in endometrial cancer
Published 5 years ago • 991 plays • Length 1:32Download video MP4
Download video MP3
Similar videos
-
1:39
dr. makker on synergy between lenvatinib and pembrolizumab in endometrial cancer
-
0:57
dr. makker on combination approaches in endometrial cancer
-
1:41
dr. makker on unmet needs for patients with advanced endometrial cancer
-
0:52
dr. zamarin on lenvatinib plus pembrolizumab in endometrial cancer
-
1:03
dr. makker discusses immunogenicity in endometrial cancer
-
0:13
copy of dr. makker on combination approaches in endometrial cancer
-
1:22
dr. zamarin on the role of pembrolizumab in endometrial cancer
-
0:53
dr. backes on next steps for lenvatinib and weekly paclitaxel in endometrial cancer
-
0:55
dr. backes on safety profile of lenvatinib and weekly paclitaxel in endometrial cancer
-
0:46
modest response rates in endometrial cancers
-
57:40
immunotherapy in endometrial cancer: expanding horizons
-
0:58
dr. oaknin on the garnet study in endometrial cancer
-
3:28
keynote-775 subgroup analysis in advanced endometrial cancer
-
4:02
#esmo19: lenvatinib (len) and pembrolizumab (pembro) in advanced endometrial cancer
-
1:07
dr. oaknin on the safety profile of dostarlimab in endometrial cancer
-
8:23
high reward, high toxicity: combination pembrolizumab and lenvatinib in advanced endometrial cancer
-
0:47
dr. levine on immunotherapy in endometrial cancer
-
1:02
dr. klopp discusses chemoradiation in endometrial cancer
-
1:01
dr. backes on the film trial in endometrial cancer